Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
10.38
-0.10 (-0.95%)
At close: Mar 28, 2025, 4:00 PM
10.30
-0.08 (-0.76%)
Pre-market: Mar 31, 2025, 8:41 AM EDT

Company Description

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.

The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.

The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform.

It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis.

The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.
Roivant Sciences logo
Country United Kingdom
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 908
CEO Matthew Gline

Contact Details

Address:
50 Broadway, 7th Floor
London, SW1H 0DB
United Kingdom
Phone 44 20 7400 3347
Website roivant.com

Stock Details

Ticker Symbol ROIV
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001635088
CUSIP Number G76279101
ISIN Number BMG762791017
Employer ID 98-1173944
SIC Code 2834

Key Executives

Name Position
Matthew Gline Chief Executive Officer and Director
Dr. Mayukh Sukhatme M.D. President, Chief Investment Officer and Director
Richard Pulik Chief Financial Officer
Dr. Eric Venker M.D., Pharm.D. President and Chief Operating Officer
Drew Kramer Chief Information Officer
Josh Chen J.D. General Counsel
Kelly Graff Head of People
Alex Gasner Executive Vice President of Roivant Health
Dr. Matt Maisak Chief Operating Officer of Roivant Platforms
Dr. Srini Ramanathan Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Mar 20, 2025 144 Filing
Mar 20, 2025 8-K Current Report
Mar 20, 2025 144 Filing
Mar 19, 2025 8-K Current Report
Feb 21, 2025 8-K Current Report
Feb 20, 2025 144 Filing
Feb 18, 2025 144/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 13, 2025 144 Filing